208 related articles for article (PubMed ID: 26544894)
1. Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis.
Vici P; Di Benedetto A; Ercolani C; Pizzuti L; Di Lauro L; Sergi D; Sperati F; Terrenato I; Dattilo R; Botti C; Fabi A; Ramieri MT; Mentuccia L; Marinelli C; Iezzi L; Gamucci T; Natoli C; Vitale I; Barba M; Mottolese M; De Maria R; Maugeri-Saccà M
Oncotarget; 2015 Dec; 6(40):42773-80. PubMed ID: 26544894
[TBL] [Abstract][Full Text] [Related]
2. Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.
Barba M; Vici P; Pizzuti L; Di Lauro L; Sergi D; Di Benedetto A; Ercolani C; Sperati F; Terrenato I; Botti C; Mentuccia L; Iezzi L; Gamucci T; Natoli C; Vitale I; Mottolese M; De Maria R; Maugeri-Saccà M
BMC Cancer; 2017 Feb; 17(1):101. PubMed ID: 28166748
[TBL] [Abstract][Full Text] [Related]
3. DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis.
Vici P; Buglioni S; Sergi D; Pizzuti L; Di Lauro L; Antoniani B; Sperati F; Terrenato I; Carosi M; Gamucci T; Dattilo R; Bartucci M; Vincenzoni C; Mariani L; Vizza E; Sanguineti G; Gadducci A; Vitale I; Barba M; De Maria R; Mottolese M; Maugeri-Saccà M
PLoS One; 2016; 11(3):e0149872. PubMed ID: 26930412
[TBL] [Abstract][Full Text] [Related]
4. Constitutive expression of γ-H2AX has prognostic relevance in triple negative breast cancer.
Nagelkerke A; van Kuijk SJ; Sweep FC; Nagtegaal ID; Hoogerbrugge N; Martens JW; Timmermans MA; van Laarhoven HW; Bussink J; Span PN
Radiother Oncol; 2011 Oct; 101(1):39-45. PubMed ID: 21840613
[TBL] [Abstract][Full Text] [Related]
5. DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.
Ronchetti L; Melucci E; De Nicola F; Goeman F; Casini B; Sperati F; Pallocca M; Terrenato I; Pizzuti L; Vici P; Sergi D; Di Lauro L; Amoreo CA; Gallo E; Diodoro MG; Pescarmona E; Vitale I; Barba M; Buglioni S; Mottolese M; Fanciulli M; De Maria R; Maugeri-Saccà M
Int J Cancer; 2017 Jun; 140(11):2587-2595. PubMed ID: 28233295
[TBL] [Abstract][Full Text] [Related]
6. Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
Domagala P; Hybiak J; Rys J; Byrski T; Cybulski C; Lubinski J
Oncotarget; 2016 Oct; 7(42):68662-68673. PubMed ID: 27626685
[TBL] [Abstract][Full Text] [Related]
7. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
9. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
Akashi-Tanaka S; Watanabe C; Takamaru T; Kuwayama T; Ikeda M; Ohyama H; Mori M; Yoshida R; Hashimoto R; Terumasa S; Enokido K; Hirota Y; Okuyama H; Nakamura S
Clin Breast Cancer; 2015 Feb; 15(1):80-5. PubMed ID: 25445419
[TBL] [Abstract][Full Text] [Related]
10. Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.
Spugnesi L; Gabriele M; Scarpitta R; Tancredi M; Maresca L; Gambino G; Collavoli A; Aretini P; Bertolini I; Salvadori B; Landucci E; Fontana A; Rossetti E; Roncella M; Naccarato GA; Caligo MA
Genes Chromosomes Cancer; 2016 Dec; 55(12):915-924. PubMed ID: 27328445
[TBL] [Abstract][Full Text] [Related]
11. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
12. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer.
Chae S; Kang KM; Kim HJ; Kang E; Park SY; Kim JH; Kim SH; Kim SW; Kim EK
Curr Oncol; 2018 Apr; 25(2):e113-e119. PubMed ID: 29719435
[TBL] [Abstract][Full Text] [Related]
14. CD10 expression as a potential predictor of pathological complete response in ER-negative and triple-negative breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.
Dimitrov G; Shousha S; Troianova P
Exp Mol Pathol; 2024 Feb; 135():104885. PubMed ID: 38281565
[TBL] [Abstract][Full Text] [Related]
15. [Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
Liu L; Li XR; Hu YH; Zhang J
Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(12):940-3. PubMed ID: 27045718
[TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.
Wang RX; Chen S; Huang L; Shao ZM
BMC Cancer; 2018 Sep; 18(1):909. PubMed ID: 30241470
[TBL] [Abstract][Full Text] [Related]
17. Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy.
Watanabe Y; Maeda I; Oikawa R; Wu W; Tsuchiya K; Miyoshi Y; Itoh F; Tsugawa K; Ohta T
Genes Cells; 2013 Dec; 18(12):1120-30. PubMed ID: 24581343
[TBL] [Abstract][Full Text] [Related]
18. Predictive markers for pathological complete response after neo-adjuvant chemotherapy in triple-negative breast cancer.
Van Bockstal MR; Noel F; Guiot Y; Duhoux FP; Mazzeo F; Van Marcke C; Fellah L; Ledoux B; Berlière M; Galant C
Ann Diagn Pathol; 2020 Dec; 49():151634. PubMed ID: 32987254
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response.
Al-Kaabi MM; Alshareeda AT; Jerjees DA; Muftah AA; Green AR; Alsubhi NH; Nolan CC; Chan S; Cornford E; Madhusudan S; Ellis IO; Rakha EA
Br J Cancer; 2015 Mar; 112(5):901-11. PubMed ID: 25688741
[TBL] [Abstract][Full Text] [Related]
20. Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Humbert O; Riedinger JM; Charon-Barra C; Berriolo-Riedinger A; Desmoulins I; Lorgis V; Kanoun S; Coutant C; Fumoleau P; Cochet A; Brunotte F
Clin Cancer Res; 2015 Dec; 21(24):5460-8. PubMed ID: 26130460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
